About Us
Led by a team of distinguished life sciences leaders, Kiniksa is a global biopharmaceutical company that finds and delivers novel treatments for patients with a significant unmet need.
Our leadership team
At Kiniksa, we focus on cultivating a highly skilled and passionate team determined to deliver the promise of transformative therapies to the patients who need them most.
Our Focus
Passionate employees that are relentless and determined to put patients first.
A robust pipeline of product candidates across various stages of development.
Focus on immune modulation that targets unmet needs and underserved conditions to deliver life-changing treatment.
Strong biologic rationale and validated mechanisms to further our understanding of these therapies through research and development.
Potential for multiple indications with broad applications across multiple therapeutic categories.
Image
Our History
Image
Founded in 2015, Kiniksa Pharmaceuticals is a global biopharmaceutical company dedicated to advancing novel, transformative therapies for patients with unmet medical needs, with a focus on cardiovascular diseases.
With a portfolio that includes an FDA-approved therapy and clinical-stage assets, Kiniksa continues to advance its pipeline with product candidates that offer strong biologic rationale, validated pathways or mechanisms, and potential for differentiation.
Key Milestones
2022
Q1
Kiniksa and Huadong Medicine announce strategic collaboration to develop and commercialize Kiniksa’s ARCALYST® (rilonacept) and mavrilimumab in the Asia Pacific Region (excluding Japan).
Q3
Kiniksa announces global license agreement with Roche and Genentech for the rights to develop and commercialize vixarelimab.
2021
Q2
FDA approval and commercial availability of first and only FDA-approved therapy for recurrent pericarditis on prescription basis in the US.
Q2
Kiniksa announces positive results for mavrilimumab Phase 2 trial in non-mechanically ventilated severe COVID-19 patients.
2020
Q3
FDA grants Orphan Drug designation for rilonacept and mavrilimumab.
Q4
FDA grants Breakthrough Therapy designation to vixarelimab for pruritus associated with prurigo nodularis.
2019
Q4
Initiates a first-in-human study with antigen challenge TDAR for KPL-404.
Q4
FDA grants Breakthrough Therapy designation for rilonacept for recurrent pericarditis and final Phase 2 clinical data presented at the American Heart Association 2019 Scientific Sessions.
2018
Q2
Raises $170.7M in gross proceeds from IPO.
Q2
Presents initial proof-of-concept data for rilonacept.
2017
Q3
Acquires the rights to rilonacept and receives an exclusive option to acquire KPL-404.
2016
Q3
Acquires the worldwide rights to our first program (rilonacept) and initiates IND-enabling activities.
2015
Q4
Kiniksa raises $80M in committed Series A capital to focus on rapidly bringing therapies to patients who have unmet needs.
Driven and determined, our leadership team has a proven track record of doing what it takes to make a difference in patients’ lives.
Our track record of successful in-licensing and out-licensing transactions underscores our commitment to innovation, speed,
and strong collaboration. We are actively focused on expanding our pipeline with novel, high-impact programs and platforms.
Every member of the Kiniksa team has an unwavering commitment to acting with integrity in our mission to help patients.
We’re dedicated to supporting healthcare improvements for people living with devastating diseases within our therapeutic areas of interest. Discover our grants and sponsorship programs.